InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,600.40
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.48
(
0.42%
)
Bitcoin
63,519.22
(
-0.75%
)
Post# of 251732
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 127375

Friday, 06/08/2012 8:18:57 AM

Friday, June 08, 2012 8:18:57 AM

Post# of 251732
FDA extends NDA review of NVO’s Tresiba (a/k/a degludec) long-acting insulin by three months:

http://in.reuters.com/article/2012/06/08/us-novonordisk-degludec-fda-idINBRE85709520120608

The extension also affects the FDA’s concurrent review of Ryzodeg (a/k/a degludecplus), which is a combination of degludec and NVO’s NovoLog mealtime insulin. The new PDUFA date for both products is 10/29/12.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up